Table 2.
Associations among ALDH, HIF1A, and HIF2A before neoadjuvant chemotherapy, with clinical and pathological parameters, in 75 patients with locally advanced breast cancer subjected to neoadjuvant epirubicin and docetaxel combination.
| ALDH | HIF1A | HIF2A | ||||||
| Parameter | Positive(n = 25) | Negative(n = 50) | p* | Positive(n = 38) | Negative(n = 37) | p* | QS (median) | p** |
| Age (mean ± SD) | 45±10 | 51±11 | 0.02 | 47±11 | 51±11 | 0.1 | r = −0.11 | 0.3 |
| Menopausal status (n) | ||||||||
| Pre | 18 | 26 | 24 | 19 | 100 | |||
| Post | 7 | 24 | 0.09 | 14 | 18 | 0.3 | 55 | 0.1 |
| Clinical stage (n) | ||||||||
| II | 14 | 23 | 17 | 20 | 80 | |||
| III | 11 | 27 | 0.4 | 21 | 17 | 0.5 | 80 | 0.9 |
| Grade (n) | ||||||||
| 1/2 | 17 | 40 | 25 | 33 | 65 | |||
| 3 | 8 | 10 | 0.2 | 13 | 4 | 0.02 | 100 | 0.2 |
| ER positive (n) | 16 | 32 | 1.0 | 21 | 28 | 0.08 | 80 | 0.8 |
| PgR positive (n) | 11 | 23 | 1.0 | 15 | 20 | 0.2 | 75 | 0.9 |
| HER2 positive (n) | 7 | 13 | 1.0 | 12 | 8 | 0.4 | 60 | 0.4 |
| Clinical response (n) | ||||||||
| OR | 20 | 41 | 33 | 28 | 80 | |||
| NR | 5 | 9 | 1.0 | 5 | 9 | 0.2 | 70 | 0.8 |
| pCR (n) | 4 | 6 | 0.7 | 8 | 2 | 0.03 | 90 | 0.6 |
| ALN (n) | ||||||||
| Positive | 12 | 31 | 18 | 25 | 65 | |||
| Negative | 12 | 19 | 0.4 | 19 | 12 | 0.09 | 100 | 0.08 |
ER, estrogen receptor; OR, objective response; NR, no response; pCR, complete pathological response; ALN, axillary lymph node; * Fisher's exact test; **median test.